2.33

5.43% 0.12

Pre-market: 2.22 -0.11 -4.72%

Allogene Therapeutics Inc (ALLO)

Overview News Price History Option Chain Financials Discussions Forecast

Allogene Therapeutics Inc stock is traded at $2.33, with a volume of 4.40M. It is up +5.43% in the last 24 hours and down -7.91% over the past month. Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Previous Close:

$2.21

Open:

$2.27

24h Volume:

4.40M

Relative Volume:

0.79

Market Cap:

$568.00M

Revenue:

$22,000

Net Income/Loss:

$-190.89M

P/E Ratio:

-2.6837

EPS:

-0.8682

Net Cash Flow:

$-149.63M

1W Performance:

+8.37%

1M Performance:

-7.91%

6M Performance:

+94.17%

1Y Performance:

+45.62%

1-Day Range:

$2.26

$2.37

1-Week Range:

$2.055

$2.60

52-Week Range:

$0.8621

$2.80

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name

Allogene Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(650) 457-2700

Address

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO

Employee

152

Twitter

@AllogeneTx

Next Earnings Date

2026-03-12

Latest SEC Filings

ALLO's Discussions on Twitter

Compare ALLO vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALLO Allogene Therapeutics Inc	2.33	538.75M	22,000	-190.89M	-149.63M	-0.8682
VRTX Vertex Pharmaceuticals Inc	454.97	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	31.97B	606.42M	-1.28B	-997.58M	-6.403

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-09-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Oct-10-25	Downgrade	JP Morgan	Neutral → Underweight
May-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Mar-14-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Aug-08-24	Resumed	Oppenheimer	Outperform
May-31-24	Initiated	Piper Sandler	Overweight
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy
Jun-03-22	Initiated	Robert W. Baird	Neutral
Feb-28-22	Reiterated	B. Riley Securities	Buy
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Goldman	Buy → Neutral
Oct-08-21	Downgrade	Stifel	Buy → Hold
Sep-23-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-21-21	Resumed	Jefferies	Buy
May-20-21	Upgrade	Truist	Hold → Buy
May-14-21	Initiated	B. Riley Securities	Buy
Jan-26-21	Upgrade	Stifel	Hold → Buy
Dec-10-20	Resumed	H.C. Wainwright	Buy
Nov-24-20	Initiated	BofA Securities	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Outperform
Jun-01-20	Downgrade	Raymond James	Outperform → Mkt Perform
May-29-20	Reiterated	H.C. Wainwright	Buy
May-19-20	Upgrade	ROTH Capital	Neutral → Buy
May-15-20	Upgrade	Guggenheim	Neutral → Buy
May-14-20	Reiterated	H.C. Wainwright	Buy
May-14-20	Downgrade	SunTrust	Buy → Hold
Apr-13-20	Initiated	SunTrust	Buy
Mar-13-20	Initiated	H.C. Wainwright	Buy
Mar-05-20	Initiated	Stifel	Hold
Feb-24-20	Initiated	Berenberg	Hold
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Nov-04-19	Initiated	Canaccord Genuity	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-05-19	Initiated	ROTH Capital	Neutral
May-31-19	Initiated	Guggenheim	Neutral
May-23-19	Initiated	Stifel	Hold
Mar-29-19	Initiated	Piper Jaffray	Overweight

View All

Allogene Therapeutics Inc Stock (ALLO) Latest News

Mar 24, 2026

If You Invested $1,000 in Allogene Therapeutics (ALLO) - Stock Titan

Mar 24, 2026

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 9.2%Here's Why - MarketBeat

Mar 24, 2026

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 24, 2026

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 earnings call transcript - MSN

Mar 24, 2026

Mar 23, 2026

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Mar 23, 2026

Allogene Therapeutics (NASDAQ:ALLO) Shares Up 11.4%Time to Buy? - MarketBeat

Mar 23, 2026

Piper Sandler analysts bullish on Allogene Therapeutics (ALLO) ahead of key ALPHA3 data readout - MSN

Mar 23, 2026

Mar 22, 2026

Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index - marketscreener.com

Mar 22, 2026

Mar 21, 2026

Allogene targets pivotal ALPHA3 data in April and extends cash runway into 2028 while prioritizing scalable CAR T programs - MSN

Mar 21, 2026

Mar 20, 2026

Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout - Insider Monkey

Mar 20, 2026

Mar 18, 2026

Allogene Therapeutics (NASDAQ:ALLO) SVP Sells $11,942.45 in Stock - MarketBeat

Mar 18, 2026

David Chang Sells 47,763 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock - MarketBeat

Mar 18, 2026

Allogene (NASDAQ: ALLO) SVP share sale funds tax withholding - Stock Titan

Mar 18, 2026

Allogene (ALLO) CEO executes 47,763-share tax sell-to-cover transaction - Stock Titan

Mar 18, 2026

Allogene Therapeutics targets new approach to autoimmune conditions with ALLO-329 - Traders Union

Mar 18, 2026

Mar 17, 2026

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 5.1%Time to Sell? - MarketBeat

Mar 17, 2026

Take the Zacks approach to beat the markets: Starbucks, Amgen, Allogene in focus - MSN

Mar 17, 2026

Form 144 Allogene Therapeutics For: 16 March By Investing.com - Investing.com Australia

Mar 17, 2026

Mar 16, 2026

Allogene Therapeutics (NASDAQ: ALLO) proposes sale of 4,835 shares - Stock Titan

Mar 16, 2026

Allogene Therapeutics (NASDAQ: ALLO) RSUs Vest, 47,763 Common Shares - Stock Titan

Mar 16, 2026

Citizens reiterates Allogene stock rating on pipeline progress - Investing.com

Mar 16, 2026

Citizens reiterates Allogene stock rating on pipeline progress By Investing.com - Investing.com UK

Mar 16, 2026

Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Expands By 19.8% - MarketBeat

Mar 16, 2026

Form 144 Allogene Therapeutics For: 16 March - Investing.com

Mar 16, 2026

Mar 14, 2026

Allogene Therapeutics Banks on 2026 Trial Catalysts - The Globe and Mail

Mar 14, 2026

Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com

Mar 14, 2026

El Pollo Loco Posts Upbeat Q4 Results, Joins Kyivstar Group, American Public Education And Other Big Stocks Moving Higher On Friday - Sahm

Mar 14, 2026

Analysts Are Bullish on Top Healthcare Stocks: Equillium (EQ), Qiagen (QGEN) - The Globe and Mail

Mar 14, 2026

Mar 13, 2026

Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Allogene Therapeutics (ALLO) - The Globe and Mail

Mar 13, 2026

Canaccord Genuity Group Reiterates Buy Rating for Allogene Therapeutics (NASDAQ:ALLO) - MarketBeat

Mar 13, 2026

Allogene Therapeutics posts narrower-than-expected loss in Q4 - MSN

Mar 13, 2026

Canaccord Genuity Maintains Buy Rating for ALLO with $14 Target - GuruFocus

Mar 13, 2026

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat

Mar 13, 2026

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - AOL.com

Mar 13, 2026

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision - AOL.com

Mar 13, 2026

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - The Globe and Mail

Mar 13, 2026

Allogene Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Mar 13, 2026

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 13, 2026

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Q32 Bio (QTTB) - The Globe and Mail

Mar 13, 2026

Allogene Therapeutics (ALLO) Projects Key Milestones for 2026 - GuruFocus

Mar 13, 2026

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update - Sahm

Mar 13, 2026

Mar 12, 2026

Allogene Therapeutics 2025 Annual Report: Advancing Allogeneic CAR T Cell Therapies for Cancer and Autoimmune Diseases - Minichart

Mar 12, 2026